BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Shenzhen Forward Pharmaceuticals Co.\, Ltd. readouts · AssetM
 emo
X-WR-CALDESC:Upcoming readouts of studies Shenzhen Forward Pharmaceuticals 
 Co.\, Ltd.'s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07002177-9147@assetmemo.bio
DTSTAMP:20261121T005931Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:FWD1802: Phase 1/2 readout est. (NCT07002177)
DESCRIPTION:FWD1802\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD18
 02 in Patients With ER+/HER2- BC\nEstimated primary completion: 1 May 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/fwd1802#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07002177
URL:https://assetmemo.bio/drug/fwd1802#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
